rheumatology
Rare diseases

JAK inhibitors the ‘new therapeutic paradigm’ in ankylosing spondylitis

The oral Janus kinase (JAK) inhibitor, upadacitinib, is emerging as a potential new treatment option for patients with ankylosing spondylitis (AS) according to results from a phase 2/3 study. The drug, which is not yet available in Australia, is approved in the US and Europe to treat rheumatoid arthritis (RA) but has recently been explored ...

Already a member?

Login to keep reading.


OR
© 2021 the limbic